North of Tyne Area Prescribing Committee Agenda

North of Tyne
Area Prescribing Committee
(www.northoftyneapc.nhs.uk)
Tuesday 13th November 2012.
Room 3, Northumbria House, Unit 7/8 Silver Fox Way, Cobalt Business Park.
The meeting will start at 12:30pm

AGENDA

1.  / Apologies for absence
2.  / Declarations of interest
·  Relevant declarations
3. / Appeals against previous decisions
·  Hyalofemme / Enclosure t/f
4. / Minutes and decision summary from the meeting held on 11/9/12 / Email sent 21/9/12
5. / Matters arising/actions from previous meeting
·  Review of NPC Diagnostic tool on Local Decision Making / Enclosed with agenda
6. / Report from the Formulary sub-group
·  Unapproved minutes from meeting held on 18/10/12
·  Decision summary from meeting held on 18/10/12
·  Formulary version 4.0
·  Emollients review / Enclosed with agenda
Enclosed with agenda
Updated on website
Enclosed with agenda
7. / Report from the Shared Care Group
·  Minutes from 13/6/12
·  Draft minutes from 17/10/12
·  Shared Care Guidelines for the Monitoring of Erythropoietin(Darbepoetin [Aranesp])in the Treatment of Patients with Chronic Kidney Disease (CKD)
·  Traffic Light list 09/12 / Enclosed with agenda
Enclosed with agenda
Enclosed with agenda
Updated on website
8. / Report from the Antimicrobial Chemotherapy Sub-group
·  No meeting
9. / Report from Medicines Management QIPP Sub-group
·  No meeting
10. / Tadalafil – Adcirca branded prescribing / Enclosed with agenda
11. / Primary care rebate schemes for medicines / Enclosed with agenda
12. / Documents previously circulated by e-mail
·  NECDAG Cancer Drug Fund Decision Document - Clofarabine (Evoltra®) for patients with refractory of relapsed AML who are non-responders to FLAG prior to allograft
·  NECDAG Cancer Drug Fund Decision Document - Everolimus (Afinitor®) for unresectable or metastatic advanced pancreatic neuroendocrine tumours.
·  NECDAG Cancer Drug Fund Decision Document -
Everolimus (Afinitor®) for the treatment of hormone receptor-positive HER2 -ve advanced breast cancer, in combination with exemestane.
·  NECDAG Gateway decision – Gemcitabine - Ovarian cancer
·  NECDAG Gateway decision - PEG Asparginase for adult patients with ALL
·  NECDAG Gateway decision - Rituximab + salvage chemotherapy for patients relapsing > 12 months post 1st line therapy with R-CHOP
·  NECDAG Gateway decision – Rituximab for rising EBV viral copy numbers in patients after allogenic bone marrow transplant to pre-empt development of Post Transplant Lymphoproliferative disorders (PTLD)
·  NECDAG Decision Document - Intravesical Mitomycin C combined with thermotherapy (Synergo®)
·  NECDAG Decision Document - Rituximab in combination with bendamustine for CLL.
·  NECDAG Decision Document - Rituximab in combination with bendamustine for the treatment of low grade Non Hodgkins lymphoma (NHL).
·  NECDAG Decision Document - Rituximab in combination with bendamustine for the treatment of High Grade Non Hodgkins lymphoma (NHL). / Email sent 24/10/12
Email sent 24/10/12
Email sent 24/10/12
Email sent 24/10/12
Email sent 24/10/12
Email sent 24/10/12
Email sent 24/10/12
Email sent 24/10/12
Email sent 24/10/12
Email sent 24/10/12
Email sent 24/10/12
13. / APC Guidelines and Statements for review
14. / NICE Technology Appraisals published September and October
·  TA264 - Stroke (acute, ischaemic) - alteplase
·  TA265- Bone metastases from solid tumours - denosumab
15. / Chairman’s action
·  Exenatide Information sheet
·  Tacrolimus information sheet
·  Melatonin - information for primary care (updated) / {Circulated for {comment 24/9/12 and updated on website
Updated on website
16. / Any other business
17. / Date and time of next meeting:
Tuesday 8th January 2013
Room 3, Northumbria House, Unit 7/8 Silver Fox Way, Cobalt Business Park, North Tyneside.
The meeting will start at 12:30pm

Page 1 of 3